Skip to Content
Search Menu

Bladder Cancer: The Danish TOMBOLA Shows Practice Changing Results

Dag Stormoen, MD and PhD student, Department of Oncology, Rigshospitalet presented highlights and Danish perspectives on bladder cancer at the Danish Evening at ESMO 2024.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Highlights From the Nordic Urothelial Cancer Oncology Group (NUCOG)

/ Katrine Ørum / Helle Pappot / Anders Ullén
Bladder cancer
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Bladder cancer Play the Video 08:59

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Bladder cancer
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25Bladder cancerType 2-diabetes Play the Video 02:42
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Bladder cancer Play the Video 06:12
Helen Moon

Influence of Tumor Burden on Treatment Strategies and Clinical Outcomes in LA/mUC Patients Receiving Avelumab First-Line Maintenance: Insights from Real-World Data

/ Helen Moon
ASCOGU25Bladder cancer Play the Video 05:23
Interview With Thomas Powles

Maximizing the Tolerability of Enfortumab Vedotin + Pembrolizumab – The Upcoming New Standard Treatment for Advanced Bladder Cancer

/ Thomas Powles
Bladder cancer Play the Video 05:55

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Gastrointestinal cancer
Back to top